Cited by

• The timing of introduction of pharmaceutical innovations in seven European countries.

  Westerling R, Westin M, McKee M, Hoffmann R, Plug I, Rey G, Jougla E, Lang K, Pärna K, Alfonso JL, Mackenbach JP. Westerling R, et al. J Eval Clin Pract. 2014 Aug;20(4):301-10. doi: 10.1111/jep.12122. Epub 2014 Apr 22. J Eval Clin Pract. 2014. PMID: 24750393 Free PMC article.
• Inhibition of human immunodeficiency virus replication by the herpes simplex virus virion host shutoff protein.

  Hamouda T, McPhee R, Hsia SC, Read GS, Holland TC, King SR. Hamouda T, et al. J Virol. 1997 Jul;71(7):5521-7. doi: 10.1128/JVI.71.7.5521-5527.1997. J Virol. 1997. PMID: 9188626 Free PMC article.
• Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity.

  Huang LM, Joshi A, Willey R, Orenstein J, Jeang KT. Huang LM, et al. EMBO J. 1994 Jun 15;13(12):2886-96. doi: 10.1002/j.1460-2075.1994.tb06583.x. EMBO J. 1994. PMID: 8026473 Free PMC article.
• HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.

  Becker Y. Becker Y. Virus Genes. 1994 Jul;8(3):249-70. doi: 10.1007/BF01704519. Virus Genes. 1994. PMID: 7975271 Review.
• The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes.

  Rice WG, Schaeffer CA, Graham L, Bu M, McDougal JS, Orloff SL, Villinger F, Young M, Oroszlan S, Fesen MR, et al. Rice WG, et al. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9721-4. doi: 10.1073/pnas.90.20.9721. Proc Natl Acad Sci U S A. 1993. PMID: 7692451 Free PMC article.